Changeflow GovPing Pharma & Drug Safety Tumor Infiltrating Lymphocytes Therapy
Routine Rule Added Final

Tumor Infiltrating Lymphocytes Therapy

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4329782A1 for Alethia Biotherapeutics ULC covering tumor infiltrating lymphocytes (TIL) therapy for cancer treatment. The application includes 17 IPC classifications including cell compositions, antibodies, and combination therapies. The patent designates 35 European states including Germany, France, UK, Italy, Spain, and the Netherlands.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The European Patent Office published EP4329782A1, a patent application for tumor infiltrating lymphocytes (TIL) therapy filed by Alethia Biotherapeutics ULC. The application covers therapeutic compositions and methods for treating cancer using infiltrating lymphocytes, including combination therapies with antibodies and chemotherapy agents.

Affected parties including pharmaceutical companies, biotech firms, and researchers developing cell-based cancer immunotherapies should monitor this patent for potential licensing implications or freedom-to-operate considerations in European markets.

Archived snapshot

Apr 19, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

TUMOR INFILTRATING LYMPHOCYTES THERAPY

Publication EP4329782A1 Kind: A1 Apr 08, 2026

Applicants

Alethia Biotherapeutics ULC

Inventors

FILION, Mario

IPC Classifications

A61K 35/17 20150101AFI20250402BHEP A61K 31/337 20060101ALI20250402BHEP A61K 39/395 20060101ALI20250402BHEP A61P 35/00 20060101ALI20250402BHEP A61P 35/04 20060101ALI20250402BHEP C07D 305/14 20060101ALI20250402BHEP C07K 16/18 20060101ALI20250402BHEP C12N 5/078 20100101ALI20250402BHEP A61K 39/00 20060101ALI20250402BHEP A61K 31/704 20060101ALI20250402BHEP A61K 40/11 20250101ALI20250402BHEP A61K 40/42 20250101ALI20250402BHEP C12N 5/0781 20100101ALI20250402BHEP C12N 5/0783 20100101ALI20250402BHEP A61K 45/06 20060101ALI20250402BHEP C07K 16/30 20060101ALI20250402BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4329782A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent filing IP registration
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!